Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: Case of the BOLERO-2 trial

Breast Cancer Research and Treatment

Volumn 146, Issue 3, 2014, Pages 669-673

  Diaby, Vakaramoko ^a   Adunlin, Georges ^a   Ali, Askal Ayalew ^a   Tawk, Rima ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

BOLERO 2 trial; Breast cancer; Progression free survival; Quality adjusted progression free survival; Utilities

Indexed keywords

ANTINEOPLASTIC AGENT; EVEROLIMUS; EXEMESTANE; PLACEBO; ANDROSTANE DERIVATIVE; BENTHIOCARB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; RAPAMYCIN; THIOCARBAMIC ACID DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL TIME; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GENETICS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANDROSTADIENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIROLIMUS; THIOCARBAMATES; TREATMENT OUTCOME;

EID: 84907365950     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3047-y     Document Type: Article

References (13)

1. Drummond MF, Schwartz JS, Jönsson B et al (2008) Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care 24:244-258 (Pubitemid 351950160)
2. Verduyn SC, Biesma B, Schramel F et al (2012) Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non-small cell lung cancer patients in The Netherlands. Health Qual Life Outcomes 10:108
3. Baselga J, Campone M, Piccart M et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520-529
4. Burris HA, Lebrun F, Rugo HS et al (2013) Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer 119(10):1908-1915
5. Kim E, Ko S, Kang H (2012) Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients. Qual Life Res 21:1193-1203
6. Versteegh MM, Rowen D, Brazier JE et al (2010) Mapping onto EQ-5D for patients in poor health. Health Qual Life Outcomes 8:141
7. Rowen D, Brazier J, Roberts J (2009) Mapping SF-36 onto the EQ-5D index: how reliable is the relationship. Health Qual Life Outcomes 7:27
8. Kim SH, Jo M, Kim H et al (2012) Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients. Health Qual Life Outcomes 10:151
9. Lloyd A, Nafees B, Narewska J et al (2006) Health state utilities for metastatic breast cancer. Br J Cancer 95:683-690 (Pubitemid 44373482)
10. Piccart M, Baselga J, Noguchi S et al (2012) Final progressionfree survival analysis of BOLERO-2: a phase III trial of everolimus for postmenopausal women with advanced breast cancer. Chemotherapy 42:59
11. Vakaramoko D, Georges A, Alberto JM (2013) Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial. Pharmacoeconomics 32:101-108
12. Guyot P, Ades A, Ouwens MJ et al (2012) Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol 12:9
13. Lee CK, Gebski VJ, Coates AS et al (2013) Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing singleagent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone. SpringerPlus 2:1-10